🇺🇸 FDA
Patent

US 10226535

Auristatin compounds and conjugates thereof

granted A61KA61K47/59

Quick answer

US patent 10226535 (Auristatin compounds and conjugates thereof) held by Mersana Therapeutics, Inc. expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Mersana Therapeutics, Inc.
Grant date
Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K47/59